Retrophin announced a joint development agreement with Censa Pharmaceuticals to evaluate CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin (BH4) with the potential to provide improved phenylalanine (Phe) reduction in patients with PKU when compared to BH4.   Under the terms of the agreement, Retrophin is making a $10 million upfront payment to Censa and will provide funding for development of CNSA-00...